Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease

Movement Disorders

Volumn 26, Issue 4, 2011, Pages 587-598

  Stowe, Rebecca ^a   Ives, Natalie ^a   Clarke, Carl E ^a,b   Handley, Kelly ^a   Furmston, Alexandra ^a   Deane, Katherine ^c   van Hilten, J J ^d   Wheatley, Keith ^e   Gray, Richard ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Adjuvant treatment; Levodopa; Meta analysis; Motor complications; Parkinson's disease

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; ENTACAPONE; LEVODOPA; PERGOLIDE; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOLCAPONE;

ADJUVANT THERAPY; COMPARATIVE EFFECTIVENESS; CONSTIPATION; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; HALLUCINATION; HUMAN; HYPOTENSION; INSOMNIA; META ANALYSIS; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SOMNOLENCE; SYSTEMATIC REVIEW; UNIFIED PARKINSON DISEASE RATING SCALE; VOMITING; XEROSTOMIA;

ADJUVANTS, PHARMACEUTIC; ANTIPARKINSON AGENTS; CLINICAL TRIALS AS TOPIC; DISABILITY EVALUATION; ENZYME INHIBITORS; HUMANS; LEVODOPA; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 79955042878     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23517     Document Type: Review

References (60)

1. Schapira AH. Science, medicine, and the future: Parkinson's disease. BMJ 1999; 318: 311-314.
2. Quinn NP. Parkinson's disease: clinical features. Baillieres Clin Neurol 1997; 6: 1-13.
3. Clarke CE. Medical management of Parkinson's disease. J Neurol Neurosurg Psychiatry 2002; 72 ( Suppl 1): 122-127.
4. The Parkinson Study Group. Levodopa and the progression of Parkinson's disease. New Engl J Med 2004; 351: 2498-2508.
5. Fahn S. Adverse effects of levodopa. In: Olanow CW, Lieberman AD, editors. The scientific basis for the treatment of Parkinson's disease. Carnforth, England: Parthenon Publishing Group; 1992. p 89-112.
6. Stowe R, Ives N, Clarke CE, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson's disease patients with motor complications. Cochrane Database Syst Rev 2010; 7: CD007166.
7. Dickersin K, Scherer R, Lefebvre C. Systematic reviews: identifying relevant studies for systematic reviews. BMJ 1994; 309: 1286-1291.
8. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
9. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
10. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993; 2: 121-145.
11. Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer, Vol. 1. Worldwide Evidence 1985-1990. Oxford: Oxford University Press; 1990.
12. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG, editors. Systematic reviews in health care: meta-analysis in context, Second ed. London: BMJ Publication Group; 2001. pp. 285-312.
13. Schneider E, Fischer PA. Bromocriptine in the treatment of progressive stages of Parkinson's disease. Dtsch Med Wochenschr 1982; 107: 175-179.
14. Toyokura Y, Mizuno Y, Kase M, et al. Effects of bromocriptine on parkinsonism. A nation-wide collaborative double-blind study. Act Neurol Scand 1985; 72: 157-170.
15. Jansen ENH. Bromocryptine in levodopa response-losing parkinsonism. A double-blind study. Eur Neurol 1978; 17: 92-99.
16. Temlett JA, Ming A, Saling M, et al. Adjunctive therapy with bromocriptine in Parkinson's disease. S Afr Med J 1990; 78: 680-685.
17. Guttman M; the International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. Neurology 1997; 49: 1060-1065.
18. Steiger MJ, EL-Debas T, Anderson T, Findley LJ, Marsden CD. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. J Neurol 1996; 243: 68-72.
19. Hutton JT, Koller WC, Ahlskog JE, et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology 1996; 46: 1062-1065.
20. Musch B, Bonura L; the Investigator Study Group. Cabergoline once a day as adjunctive therapy to levodopa in Parkinson's disease. Mov Disord 2000; 15 ( Suppl 3): 121: P632.
21. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994; 9: 40-47.
22. Pinter MM, Pogarell O, Oertel WH. Efficacy, safety and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry 1999; 66: 436-441.
23. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007; 6: 513-520.
24. Wermuth L; the Danish Pramipexole Study Group. A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease. Eur J Neurol 1998; 5: 235-242.
25. Carsten Moller J, Oertel WH, Koster J, Pezzoli G, Provinciali L. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord 2005; 20: 602-610.
26. Wong KS, Lu C-S, Shan D-E, Yang C-C, Tsoi TH, Mok V. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease. J Neurosurg Sci 2003; 216: 81-87.
27. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997; 49: 162-168.
28. Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomised, controlled study in advanced Parkinson disease. Neurology 2007; 68: 1108-1115.
29. Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JL, Fuell D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 1996; 19: 234-245.
30. Korczyn Anti-Parkinson efficacy (L-dopa sparing effect) of ropinirole versus placebo as adjunct therapy in parkinsonian patients not optimally controlled on L-dopa. SmithKline Beecham Pharmaceuticals Report No: MY-1002/SKF-101468/CPMS-034 17; 1990.
31. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 1998; 51: 1057-1062.
32. LeWitt PA, Lyons KE, Pahwa R; SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007; 68: 1262-1267.
33. Poewe WH, Deuschl G, Gordin A, Kultalahti E-R, Leinonen M; the Celomen Study Group. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen Study). Acta Neurol Scand 2002; 105: 245-255.
34. Reichmann H, Boas J, MacMahon D, Myllyla V, Hakala A, Reinikainen K; on behalf of the ComQol Study Group. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand 2005; 111: 21-28.
35. Myllyla VV, Kultalahti E-R, Haapaniemi H, Leinonen M; the FILOMEN Study Group. Twelve-month safety of entacapone in patients with Parkinson's disease. Eur J Neurol 2001; 8: 53-60.
36. Fenelon G, Gimenez-Roldan S, Montastruc JL, et al. Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study. J Neural Transm 2003; 110: 239-251.
37. Korchounov A, Bogomazov G. Employment, medical absenteeism, and disability perception in Parkinson's disease: a pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy. Mov Disord 2006; 21: 2220-2224.
38. Mizuno Y, Kanazawa I, Kuno S, Yanagisawa N, Yamamoto M, Kondo T; the Japanese Parkinson-Entacapone Study Group. Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients. Mov Disord 2007; 22: 75-80.
39. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365: 947-954.
40. Rinne UK, Larsen JP, Siden MD, Worm-Petersen J; the Nomecomt Study Group. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 1998; 51: 1309-1314.
41. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997; 42: 747-755.
42. Im JH, Jeon BS, Lee MS, Lee WY, Kim JW, Lee MC. A multicenter, double-blind, placebo-controlled study to assess efficacy and safety of entacapone in Korean patients with Parkinson's disease experiencing end-of-dose deterioration. Mov Disord 2002; 17 ( Suppl 5): S40: P83.
43. Brooks DJ, Sagar H; the UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double-blind, six month study. J Neurol Neurosurg Psychiatry 2003; 74: 1071-1079.
44. Shan DE, Lee S-J, Chao L-Y, Yeh S-I. Gait analysis in advanced Parkinson's disease-effect of levodopa and tolcapone. Can J Neurol Sci 2001; 28: 70-75.
45. Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing-off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997; 63: 421-428.
46. Kurth MC, Adler CH, St. Hilaire M, et al. Tolcapone improves motor fluctuation and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology 1997; 48: 81-87.
47. Adler CH, Singer C, O'Brien C, et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Arch Neurol 1998; 55: 1089-1095.
48. Myllya VV, Jackson M, Larsen JP, Baas H. Efficacy and safety of tolcapone in levodopa-treated Parkinson's disease patients with "wearing-off" phenomenon: a multicentre, double-blind, randomized, placebo-controlled trial. Eur J Neurol 1997; 4: 333-341.
49. Dupont E, Burgunder J-M, Findley LJ, Olsson J-E, Dorflinger E; the Tolcapone in Parkinson's Disease Study Group II (TIPS II). Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Mov Disord 1997; 12: 928-934.
50. Rajput AH, Martin W, Saint-Hilaire M-H, Dorflinger E, Pedder S. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997; 49: 1066-1071.
51. Rabey JM, Sagi I, Huberman M, et al. Rasagiline Mesylate, a new Mao-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 2000; 23: 324-330.
52. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson's disease and motor fluctuations. The PRESTO Study Group. Arch Neurol 2005; 62: 241-248.
53. Presthus J, Hajba A. Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease. Acta Neurol Scand 1983; 95: 127-133.
54. Golbe LI, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988; 11: 45-55.
55. Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM; the Zydis Selegiline Study Group. Zydis Selegiline reduces off time in Parkinson's disease patients with motor fluctations: a 3-month, randomized, placebo-controlled study. Mov Disord 2004; 19: 426-432.
56. Shellenberger MK, Clarke A, Donoghue S. Zydis selegiline reduces "off" time and improves symptoms in patients with Parkinson's disease. Mov Disord 2000; 15 ( Suppl 3): 116: P616.
57. Olanow CW. Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. Arch Neurol 2000; 57: 263-267.
58. The Tolcapone Study Group. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Mov Disord 1999; 14: 38-44.
59. Koller W, Lees A, Doder M, Hely M; Tolcapone/Pergolide Study Group. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Mov Disord 2001; 16: 858-866.
60. Deuschl G, Vaitkus A, Fox GC, Roscher T, Schremmer D, Gordin A; CAMP Study Group. Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off. Mov Disord 2007; 22: 1550-1555.